Amgen Overview

  • Founded
  • 1980

Founded
  • Status
  • Public

  • Employees
  • 30,010

Employees
  • Stock Symbol
  • AMGN

Stock Symbol
  • Investments
  • 65

  • Share Price
  • $245.17

  • (As of Friday Closing)

Amgen General Information

Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Contact Information

Website
www.amgen.com
Formerly Known As
Applied Molecular Genetics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320-1799
  • United States
+1 (805) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amgen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$245.17 $246.53 $214.39 - $296.67 $131B 534M 2.76M $12.18

Amgen Financials Summary

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 167,365,243 167,365,243 151,375,930 155,779,207
Revenue 26,323,000 26,323,000 25,979,000 25,424,000
EBITDA 8,752,000 8,752,000 11,142,000 12,835,000
Net Income 6,552,000 6,552,000 5,893,000 7,264,000
Total Assets 65,121,000 65,121,000 61,165,000 62,948,000
Total Debt 38,945,000 38,945,000 33,309,000 32,986,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer suppo
Biotechnology
Thousand Oaks, CA
30,010 As of 2023
00.000
000000000000 00.000

000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000000000000
Cambridge, MA
0000 As of 0000
000.00
000 0000-00-00
000000&0

000000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
000000000000000
Tarrytown, NY
00000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amgen Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA 0000 000.00 000000&0
000000000 00000000 Formerly VC-backed Tarrytown, NY 00000 00000 00000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 Formerly VC-backed Boston, MA 0000 000000&0
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000&0
You’re viewing 5 of 8 competitors. Get the full list »

Amgen Patents

Amgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022023979-A Imaging system for counting and measuring size of particles in container filled with fluid Pending 04-Nov-2021 0
US-20220409817-A1 Syringes, assemblies, and methods of manufacture Pending 23-Jun-2021 000000000
US-20220401650-A1 Drug delivery device having shock absorber Pending 17-Jun-2021 0000000000
US-20220402985-A1 Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3 Pending 10-Jun-2021 0000000000
US-20220403037-A1 Anti-ccr8 antibodies and uses thereof Pending 04-Jun-2021 C07K16/2866
To view Amgen’s complete patent history, request access »

Amgen Executive Team (92)

Name Title Board Seat Contact Info
Robert Bradway Chief Executive Officer & Chairman
Peter Griffith Executive Vice President and Chief Financial Officer
Kave Niksefat Vice President & General Manager, Inflammation Business
Linda Louie Chief Accounting Officer & Vice President, Finance
Nancy Grygiel JD Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
You’re viewing 5 of 92 executive team members. Get the full list »

Amgen Board Members (22)

Name Representing Role Since
000 00000 Self Board Member 000 0000
00000 000000 00 Self Board Member 000 0000
0000000 000000 00. Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000
0000 0000000 Amgen Board Member 000 0000
You’re viewing 5 of 22 board members. Get the full list »

Amgen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amgen Investments & Acquisitions (65)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 12-Dec-2022 0000000000 000.00 Pharmaceuticals 000000 00
000000000000 20-Oct-2022 0000000000 00.00 Pharmaceuticals 000000 00
0000000 11-Oct-2022 00000 0000 00000 Drug Discovery
000000 000000 20-Jul-2022 00000 0000 0000 Biotechnology
TeneoBio 19-Oct-2021 Merger/Acquisition 00.00 Biotechnology 00000 000
You’re viewing 5 of 65 investments and acquisitions. Get the full list »

Amgen Subsidiaries (8)

Company Name Industry Location Founded
Amgen Astellas BioPharma Drug Discovery Tokyo, Japan 2013
00000 00000000 Corporate Venture Capital Thousand Oaks, CA 0000
00000 000000 000 0 Foundation Lenexa, KS 0000
000000000000 Pharmaceuticals Mountain View, CA 0000
000000 00000000 Biotechnology Reykjavik, Iceland 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Amgen ESG

Risk Overview

Risk Rating

Updated January, 28, 2023

21.92 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

0.00

Percentile

To view Amgen’s complete esg history, request access »

Amgen Exits (16)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 25-Nov-2020 00 000000000000000 00000 Completed
  • 22 buyers
00000000 23-May-2019 00000 0000 Completed
  • 2 buyers
000000 00000000 00 18-Oct-2018 000000000 000.00 Completed
  • 00000
00000000 04-Oct-2017 00000 00000 00 0000 Completed
  • 7 buyers
Akili Interactive 20-Jul-2016 Early Stage VC 000.00 Completed
  • 6 buyers
You’re viewing 5 of 16 exits. Get the full list »